This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.
Focal Segmental Glomerulosclerosis
This is a pilot/feasibility, multicenter, randomized, open label, clinical trial to test that hypothesis that plasmapheresis plus rituximab prior to or at the time of kidney transplantation can prevent recurrent FSGS in children and adults.
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
-
University of Alabama, Tuscaloosa, Alabama, United States, 35487
University of California at Davis, Davis, California, United States, 95616
Lurie Children's Hospital, Chicago, Illinois, United States, 60611
University of Iowa, Iowa City, Iowa, United States, 52242
Children's Hospital of Colorado, Aurora, Minnesota, United States, 80045
University of Minnesota, Minneapolis, Minnesota, United States, 55455
Mayo Clinic, Rochester, Minnesota, United States, 55905
Duke University, Durham, North Carolina, United States, 27708
University of Cincinnati, Cincinnati, Ohio, United States, 45221
Cincinnati Children's Hospital, Cincinnati, Ohio, United States, 45229
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
1 Year to 65 Years
ALL
No
University of Minnesota,
Michelle Rheault, MD, PRINCIPAL_INVESTIGATOR, University of Minnesota
2026-12-31